252 related articles for article (PubMed ID: 3766571)
1. Cost savings achieved through cephalosporin use review and restriction.
Dzierba SH; Reilly RT; Caselnova DA
Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
[TBL] [Abstract][Full Text] [Related]
2. Savings achieved through cephalosporin surveillance.
Katz E; Schlamowitz S
Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407
[TBL] [Abstract][Full Text] [Related]
3. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
Cramer R; Wright C
Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
[TBL] [Abstract][Full Text] [Related]
4. Drug usage review and inventory analysis in promoting rational parenteral cephalosporin therapy.
Simon WA; Thompson L; Campbell S; Lantos RL
Am J Hosp Pharm; 1975 Nov; 32(11):1116-21. PubMed ID: 1190230
[TBL] [Abstract][Full Text] [Related]
5. Financial impact of formulary revision of second-generation cephalosporins.
Andrews JD; Hafting S
Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
[TBL] [Abstract][Full Text] [Related]
6. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
Hayman JN; Sbravati EC
Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
[TBL] [Abstract][Full Text] [Related]
7. Controlling financial variables--changing prescribing patterns.
Abramowitz PW
Am J Hosp Pharm; 1984 Mar; 41(3):503-15. PubMed ID: 6367444
[TBL] [Abstract][Full Text] [Related]
8. Cost containment through restriction of cephalosporins.
Britton HL; Schwinghammer TL; Romano MJ
Am J Hosp Pharm; 1981 Dec; 38(12):1897-900. PubMed ID: 7325168
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary approach to cost reduction of C-section prophylaxis.
Todd MW; Benrubi G
Hosp Formul; 1990 Apr; 25(4):446-8, 450. PubMed ID: 10104235
[TBL] [Abstract][Full Text] [Related]
10. Methods of controlling cephalosporin use in Canadian hospitals.
Godin JP; Sketris IS; Merrett RA; Marrie TJ
Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
[TBL] [Abstract][Full Text] [Related]
11. Involving physicians in efforts to control pharmaceutical expenditures.
Shulkin DJ; McGourty ME; Bourret J
Med Interface; 1995 Aug; 8(8):85-7, 90. PubMed ID: 10144777
[TBL] [Abstract][Full Text] [Related]
12. Impact of parenteral cephalosporin regulation on pharmacy costs.
Ryan JL; Francese J
Hosp Formul; 1983 May; 18(5):510-2. PubMed ID: 10260198
[No Abstract] [Full Text] [Related]
13. Clinical pharmacist impact on parenteral cephalosporin prescribing.
Lawlor MC; Lucarotti RL
Hosp Formul; 1983 Apr; 18(4):402-4, 407-8. PubMed ID: 10259512
[TBL] [Abstract][Full Text] [Related]
14. An approach to regulating cephalosporin use and costs.
Ryan JL; Francese J
Hosp Formul; 1980 Sep; 15(9):674-6. PubMed ID: 10248357
[No Abstract] [Full Text] [Related]
15. Pharmacy U.R. cuts costs, drug use.
Mosier RL
Hosp Peer Rev; 1979 May; 4(5):70-2. PubMed ID: 10308905
[No Abstract] [Full Text] [Related]
16. Contribution of clinical pharmacists to cefazolin utilization.
Witte KW; Hatoum HT; Hoon TJ
Hosp Formul; 1987 Aug; 22(8):737-41. PubMed ID: 10283405
[TBL] [Abstract][Full Text] [Related]
17. Computer-assisted antimicrobial-use monitoring.
Inaraja MT; Paloma JM; Giráldez J; Idoate AJ; Hualde S
Am J Hosp Pharm; 1986 Mar; 43(3):664-70. PubMed ID: 3754692
[TBL] [Abstract][Full Text] [Related]
18. Cephalosporin-use restrictions in teaching hospitals.
McCloskey WW; Johnson PN; Jeffrey LP
Am J Hosp Pharm; 1984 Nov; 41(11):2359-62. PubMed ID: 6507437
[TBL] [Abstract][Full Text] [Related]
19. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs.
Abramowitz PW; Nold EG; Hatfield SM
Am J Hosp Pharm; 1982 Jul; 39(7):1176-80. PubMed ID: 7114059
[TBL] [Abstract][Full Text] [Related]
20. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
Quercia RA; Chow MS; Jay GT; Quintiliani R
Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
